Evidence map›Paper›PMID 27113574›Full record

ArticleOrganic & biomolecular chemistry2016

Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes.

Angela L Perkins, Kevin L Peterson, Thomas G Beito, Karen S Flatten, Scott H Kaufmann, Daniel A Harki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Organic & biomolecular chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Angela L PerkinsDepartment of Medicinal Chemistry, University of Minnesota, 2231 6th Street SE, Minneapolis, MN 55455, USA. daharki@umn.edu.
Kevin L PetersonDivision of Oncology Research, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA.
Thomas G BeitoMonoclonal Antibody Core, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA.
Karen S FlattenDivision of Oncology Research, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA.
Scott H KaufmannDivision of Oncology Research, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA.
Daniel A HarkiDepartment of Medicinal Chemistry, University of Minnesota, 2231 6th Street SE, Minneapolis, MN 55455, USA. daharki@umn.edu.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

The topoisomerase (topo) I-DNA covalent complex represents an attractive target for developing diagnostic antibodies to measure responsiveness to drugs. We report a new antigen, peptide , and four murine monoclonal antibodies raised against that exhibit excellent specificity for recognition of in comparison to structurally similar peptides by enzyme-linked immunosorbent assays. Although topo I-DNA complex detection was not achieved in cellular samples by these new antibodies, a new strategy for antigen design is reported.

Indexed as

AnimalsAntibodies, MonoclonalAntibody SpecificityAntigen-Antibody ReactionsAntigensCell Line, TumorDNADNA Topoisomerases, Type IEnzyme-Linked Immunosorbent AssayHumansMiceMolecular StructureNucleotidesPeptidesAntibodies, MonoclonalAntigensDNADNA Topoisomerases, Type INucleotidesPeptides

Identifiers

PMID27113574
PMCPMC4922793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.